FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362593872> ?p ?o ?g. }

• W4362593872 endingPage "6402" @default.
• W4362593872 startingPage "6402" @default.
• W4362593872 abstract "Abstract Introduction: Immunotherapy based on PD1/PDL1 and/or CTLA4 blocking antibodies has shown efficacy in the molecular subgroup of colorectal cancers (CRCs) characterized by deficient mismatch repair (MMRd). This feature, present in only 4-5% of metastatic CRCs, causes a significant increase of tumor mutational burden (TMB) and tumor neoantigens, ultimately leading to immune rejection. On the other hand, for the majority of MMR proficient (MMRp) CRCs, cytotoxic chemotherapy ± targeted agents still constitute the mainstay of the treatment Interestingly, even though it is known that cytotoxic agents induce mutations, their immunogenic potential is still not fully understood. The aim of this work is to systematically investigate the immunogenicity of chemotherapy-induced mutations in CRC. Methods: We performed a two-step experiment: first, murine CRC models were exposed to chemotherapy agents in an immune-free context (priming phase) and then challenged in immune-deficient and -proficient contexts (editing phase). Chemotherapy agents included the commonly used cytotoxic drugs 5-fluorouracil (5FU), oxaliplatin, SN38 (the active metabolite of irinotecan), cisplatin, and temozolomide, used as single drugs or combinations, in a pulsatile schedule using weekly ‘cycles’ (2 days on/5 days off) in order to mimic drug exposure in clinical settings. Whole exome sequencing (WES) was performed at baseline, and after both the priming and the editing phases. Results and discussion: WES analysis showed that cisplatin-based treatment is associated with the highest increase in TMB and predicted neoantigens when compared to 5FU-based combinations. Multiple mutational processes contribute to the accumulation of mutations upon exposure to chemotherapy, as revealed by analysis of mutational signatures. A statistically significant growth delay and increased survival was reported for tumors primed with cisplatin/temozolomide and 5FU/Oxaliplatin/SN38 (FOLFOXIRI) combinations compared to unprimed tumors in immunocompetent but not in immunodeficient mice, suggesting the active involvement of the immune system in controlling tumor growth. Sequencing data of residual (escaped) tumors at the end of the editing phase revealed a preferential loss of mutations etiologically linked to chemotherapy in the immunocompetent models, pinpointing an active immune-editing of chemotherapy-induced mutations. Conclusions: Cisplatin/temozolomide and FOLFOXIRI treatment effectively prime murine CRC models for subsequent immune rejection. These results suggest that the anticancer effect of chemotherapy treatment may be in part mediated by the immune-editing of chemotherapy-induced mutant cancer subclones. Citation Format: Pietro Paolo Vitiello, Rosaria Chilà, Giuseppe Rospo, Gaia Grasso, Giovanni Crisafulli, Alice Bartolini, Vito Amodio, Federica Di Nicolantonio, Giovanni Germano, Alberto Bardelli. The effects of cytotoxic chemotherapy on colorectal cancer immunogenicity. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 6402." @default.
• W4362593872 created "2023-04-06" @default.
• W4362593872 creator A5014069019 @default.
• W4362593872 creator A5016649801 @default.
• W4362593872 creator A5022869270 @default.
• W4362593872 creator A5024586369 @default.
• W4362593872 creator A5027430576 @default.
• W4362593872 creator A5028593479 @default.
• W4362593872 creator A5059864900 @default.
• W4362593872 creator A5064011158 @default.
• W4362593872 creator A5070323284 @default.
• W4362593872 creator A5084972491 @default.
• W4362593872 date "2023-04-04" @default.
• W4362593872 modified "2023-09-30" @default.
• W4362593872 title "Abstract 6402: The effects of cytotoxic chemotherapy on colorectal cancer immunogenicity" @default.
• W4362593872 doi "https://doi.org/10.1158/1538-7445.am2023-6402" @default.
• W4362593872 hasPublicationYear "2023" @default.
• W4362593872 type Work @default.
• W4362593872 citedByCount "0" @default.
• W4362593872 crossrefType "journal-article" @default.
• W4362593872 hasAuthorship W4362593872A5014069019 @default.
• W4362593872 hasAuthorship W4362593872A5016649801 @default.
• W4362593872 hasAuthorship W4362593872A5022869270 @default.
• W4362593872 hasAuthorship W4362593872A5024586369 @default.
• W4362593872 hasAuthorship W4362593872A5027430576 @default.
• W4362593872 hasAuthorship W4362593872A5028593479 @default.
• W4362593872 hasAuthorship W4362593872A5059864900 @default.
• W4362593872 hasAuthorship W4362593872A5064011158 @default.
• W4362593872 hasAuthorship W4362593872A5070323284 @default.
• W4362593872 hasAuthorship W4362593872A5084972491 @default.
• W4362593872 hasConcept C121608353 @default.
• W4362593872 hasConcept C126322002 @default.
• W4362593872 hasConcept C143998085 @default.
• W4362593872 hasConcept C151730666 @default.
• W4362593872 hasConcept C154317977 @default.
• W4362593872 hasConcept C202751555 @default.
• W4362593872 hasConcept C203014093 @default.
• W4362593872 hasConcept C2776694085 @default.
• W4362593872 hasConcept C2777389519 @default.
• W4362593872 hasConcept C2777701055 @default.
• W4362593872 hasConcept C2778239845 @default.
• W4362593872 hasConcept C2779343474 @default.
• W4362593872 hasConcept C2780259306 @default.
• W4362593872 hasConcept C2780962732 @default.
• W4362593872 hasConcept C502942594 @default.
• W4362593872 hasConcept C526805850 @default.
• W4362593872 hasConcept C55493867 @default.
• W4362593872 hasConcept C71924100 @default.
• W4362593872 hasConcept C86803240 @default.
• W4362593872 hasConceptScore W4362593872C121608353 @default.
• W4362593872 hasConceptScore W4362593872C126322002 @default.
• W4362593872 hasConceptScore W4362593872C143998085 @default.
• W4362593872 hasConceptScore W4362593872C151730666 @default.
• W4362593872 hasConceptScore W4362593872C154317977 @default.
• W4362593872 hasConceptScore W4362593872C202751555 @default.
• W4362593872 hasConceptScore W4362593872C203014093 @default.
• W4362593872 hasConceptScore W4362593872C2776694085 @default.
• W4362593872 hasConceptScore W4362593872C2777389519 @default.
• W4362593872 hasConceptScore W4362593872C2777701055 @default.
• W4362593872 hasConceptScore W4362593872C2778239845 @default.
• W4362593872 hasConceptScore W4362593872C2779343474 @default.
• W4362593872 hasConceptScore W4362593872C2780259306 @default.
• W4362593872 hasConceptScore W4362593872C2780962732 @default.
• W4362593872 hasConceptScore W4362593872C502942594 @default.
• W4362593872 hasConceptScore W4362593872C526805850 @default.
• W4362593872 hasConceptScore W4362593872C55493867 @default.
• W4362593872 hasConceptScore W4362593872C71924100 @default.
• W4362593872 hasConceptScore W4362593872C86803240 @default.
• W4362593872 hasIssue "7_Supplement" @default.
• W4362593872 hasLocation W43625938721 @default.
• W4362593872 hasOpenAccess W4362593872 @default.
• W4362593872 hasPrimaryLocation W43625938721 @default.
• W4362593872 hasRelatedWork W1977793218 @default.
• W4362593872 hasRelatedWork W2037724349 @default.
• W4362593872 hasRelatedWork W2050348440 @default.
• W4362593872 hasRelatedWork W2069668461 @default.
• W4362593872 hasRelatedWork W2080692829 @default.
• W4362593872 hasRelatedWork W2363674970 @default.
• W4362593872 hasRelatedWork W2521675697 @default.
• W4362593872 hasRelatedWork W2545945608 @default.
• W4362593872 hasRelatedWork W2577979650 @default.
• W4362593872 hasRelatedWork W2940357394 @default.
• W4362593872 hasVolume "83" @default.
• W4362593872 isParatext "false" @default.
• W4362593872 isRetracted "false" @default.
• W4362593872 workType "article" @default.